CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
HBsAg
ROS
hepatitis B virus
rtA181T mutation
rtA181V mutation
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
11
08
2023
received:
30
12
2022
accepted:
24
08
2023
pubmed:
22
9
2023
medline:
22
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
The HBV rtA181T mutation is associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to evaluate the mechanism by which rtA181T mutation increases the risk of HCC. We enrolled 470 CHB patients with rtA181T and rtA181V mutation in this study; 68 (22.15%) of the 307 patients with rtA181T mutation and 22 (13.5%) of the 163 patients with rtA181V mutation developed HCC (p < .05). The median follow-up periods were 8.148 and 8.055 years (p > .05). Serum HBV DNA and HBsAg levels in rtA181T-positive patients were similar to that in rtA181V-positive patients. However, the serum HBeAg levels in the rtA181T-positive patients were significantly higher than that in rtA181V-positive patients. In situ hybridization experiments showed that the HBV cccDNA and HBV RNA levels were significantly higher in the liver cancer tissues of patients with the rtA181T mutation compared to that in the tissues of patients with the rtA181V mutation. The percentage of anti-tumour hot-gene site mutations was significantly higher in the rtA181T-positive HCC liver tissue compared to that in the rtA181T-negative HCC liver tissue (7.65% and 4.3%, p < .05). This is the first study to use a large cohort and a follow-up of more than 5 years (average 8 years) to confirm that the rtA181T mutation increased the risk of HCC, and that it could be related to the increase in the mutation rate of hotspots of tumour suppressor genes (CTNNB1, TP53, NRAS and PIK3CA).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
951-958Subventions
Organisme : Capital Health Research and Development Special grants
Organisme : Chinesisch-Deutsches Forschungsprojekt im Sonderprogramm zu COVID-19 (C-0012) and Key Programs of Beijing Municipal Education Commission of China
Organisme : National Key Research and Development Program of China
Organisme : Third Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Ahmedin J, Elizabeth MW, Christopher JJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109(9):djx030.
Villanueva A, Llovet JM. Liver cancer in 2013: mutational landscape of HCC-The end of the beginning. Nat Rev Clin Oncol. 2014;11(2):73-74.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-2063.
Venook AP, Papandreou C, Furuse J, Guevara L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5-13.
Lo OS, Wong LH. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622.
Anna S. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284-306.
Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2010;48:88-98.
Wong LH, Chan LY, Mak CH, Lee KY, Wong WS. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-1547.
Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A Nationwide cohort study. Gastroenterology. 2014;147:143-151.e145.
Lim Y, Han S, Heo N, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147:152-161.
Yang P, Markowitz GJ, Wang XF. The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev. 2014;1:396-412.
Kew MC. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol. 2013;12:173-182.
Brunette Gary W. CDC Health Information for International Travel 2014-The Yellow Book. CDC; 2014.
Ofliver E. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-185.
Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28:7-10.
Zhao L, Xiaodong L, Yongqian C, et al. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172*mutation. Antiviral Res. 2018;154:26-34.
Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88-98.
Li W, Warner N, Sozzi V, et al. Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. Hepatol Int. 2012;7:443-450.
Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis. 2006;193:1258-1265.
Yeh CT, Chen T, Hsu CW, et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398.
Lai MW, Huang SF, Hsu CW, Chang MH, Yeh CT. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther. 2009;14:249-261.
Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther. 2008;13:875-879.
Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003;15:247-254.
Yuan K, Lei Y, Chen HN, et al. HBV-induced ROS accumulation promotes hepatocarcinogenesis through snail-mediated epigenetic silencing of SOCS3. Cell Death Differ. 2016;23:616-627.
Tan J, Duan M, Yadav T, et al. An R-loop-initiated CSB-RAD52-POLD3 pathway suppresses ROS-induced telomeric DNA breaks. Nucleic Acids Res. 2020;48:1285-1300.
Opresko PL, Fan J, Danzy S, Wilson DM 3rd, Bohr VA. Oxidative damage in telomeric DNA disrupts recognition by TRF1 and TRF2. Nucleic Acids Res. 2005;33:1230-1239.
Fouquerel E, Barnes RP, Uttam S, Watkins SC, Bruchez MP, Opresko PL. Targeted and persistent 8-oxoguanine base damage at telomeres promotes telomere loss and crisis. Mol Cell. 2019;75:117-130.e116.
Pannunzio NR, Lieber MR. Concept of DNA lesion longevity and chromosomal translocations. Trends Biochem Sci. 2018;43:490-498.
Guo X, Wu J, Wei F, et al. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: a retrospective study. Int J Antimicrob Agents. 2018;52:201-209.
Ding H, Tu H, Qu C, Cao G, Lu S. Guideline for stratified screening and surveillance in patients with high risk of primary liver cancer (2020). Hepatoma Res. 2021;7:17. doi:10.20517/2394-5079.2021.13
Lai MW, Liang KH, Lin WR, et al. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis. 2016;5:e273.
Ivanov AV, Valuev-Elliston VT, Tyurina DA, et al. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget. 2017;8:3895-3932.
Chu VC, Bhattacharya S, Nomoto A, et al. Persistent expression of hepatitis C virus non-structural proteins leads to increased autophagy and mitochondrial injury in human hepatoma cells. PLoS One. 2011;6:e28551.
Canli Ö, Nicolas AM, Gupta J, et al. Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell. 2017;32:869-883.e865.
Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat. 2012;19:377-386.
Han SH, Tran TT. Management of chronic hepatitis B: an overview of practice guidelines for primary care providers. J Am Board Fam Med. 2015;28:822-837.
Lim SG, Marcellin P, Tassopoulos N, et al. Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 2007;26:1419-1428.
Kramata P, Votruba I, Otová B, Holý A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol. 1996;49:1005-1011.
Ahn SH, Park YK, Park ES, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818.
Yan D, Tong S, Yibo D, Cao G, et al. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12:e6031.
Chisari FV, Pinkert CA, Milich DR, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science. 1985;230:1157-1160.
Chisari FV, Filippi P, McLachlan A, et al. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol. 1986;60:880-887.
Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505-511.
Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604.
Hainaut P, Hernandez T, Robinson A, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998;26:205-213.